192 related articles for article (PubMed ID: 8347186)
1. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.
Davies B; Brown PD; East N; Crimmin MJ; Balkwill FR
Cancer Res; 1993 May; 53(9):2087-91. PubMed ID: 8347186
[TBL] [Abstract][Full Text] [Related]
2. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
3. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models.
Watson SA; Morris TM; Robinson G; Crimmin MJ; Brown PD; Hardcastle JD
Cancer Res; 1995 Aug; 55(16):3629-33. PubMed ID: 7627972
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice.
Wang X; Fu X; Brown PD; Crimmin MJ; Hoffman RM
Cancer Res; 1994 Sep; 54(17):4726-8. PubMed ID: 8062271
[TBL] [Abstract][Full Text] [Related]
6. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20.
Bu W; Tang ZY; Sun FX; Ye SL; Liu KD; Xue Q; Chen J; Gao DM
Hepatogastroenterology; 1998; 45(22):1056-61. PubMed ID: 9756006
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.
Zervos EE; Norman JG; Gower WR; Franz MG; Rosemurgy AS
J Surg Res; 1997 May; 69(2):367-71. PubMed ID: 9224409
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.
Zervos EE; Shafii AE; Haq M; Rosemurgy AS
J Surg Res; 1999 Jun; 84(2):162-7. PubMed ID: 10357914
[TBL] [Abstract][Full Text] [Related]
13. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
Eccles SA; Box GM; Court WJ; Bone EA; Thomas W; Brown PD
Cancer Res; 1996 Jun; 56(12):2815-22. PubMed ID: 8665519
[TBL] [Abstract][Full Text] [Related]
14. [An experimental study of matrix metalloproteinase inhibitor BB-94 inhibits the invasion and metastasis of the human salivary adenoid cystic carcinoma in vitro and in vivo].
Mao L; Yu S; Sun K
Zhonghua Kou Qiang Yi Xue Za Zhi; 2001 Jul; 36(4):304-7. PubMed ID: 11718018
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Deryugina EI; Soroceanu L; Strongin AY
Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
18. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
Masazza G; Lucchini V; Tomasoni A; Peccatori F; Lampasona V; Giudici G; Mangioni C; Biondi A; Giavazzi R
Cancer Res; 1991 Dec; 51(23 Pt 1):6358-62. PubMed ID: 1933898
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer.
Malik ST; Knowles RG; East N; Lando D; Stamp G; Balkwill FR
Cancer Res; 1991 Dec; 51(24):6643-9. PubMed ID: 1742738
[TBL] [Abstract][Full Text] [Related]
20. Effects of IL-12 on human ovarian tumors engrafted into SCID mice.
Silver DF; Hempling RE; Piver MS; Repasky EA
Gynecol Oncol; 1999 Feb; 72(2):154-60. PubMed ID: 10021294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]